Catherine Boileau Selected Research

Subtilisin

1/2017	The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
12/2016	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).
8/2012	Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
5/2012	Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
11/2010	Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Catherine Boileau Research Topics

Disease

26	Marfan Syndrome (Marfan's Syndrome) 01/2021 - 04/2002
22	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 05/2022 - 08/2002
12	Thoracic Aortic Aneurysm 12/2021 - 08/2006
12	Systemic Scleroderma (Systemic Sclerosis) 05/2012 - 12/2007
9	Hypercholesterolemia 05/2022 - 11/2005
8	Cardiovascular Diseases (Cardiovascular Disease) 11/2022 - 11/2005
6	Neoplasms (Cancer) 08/2015 - 08/2004
5	Coronary Disease (Coronary Heart Disease) 01/2021 - 06/2003
5	Aortic Diseases 01/2020 - 01/2015
4	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022 - 03/2011
4	Aortic Dissection 01/2021 - 12/2009
4	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 02/2015
4	Loeys-Dietz Syndrome 12/2009 - 08/2006
3	Dyslipidemias (Dyslipidemia) 05/2022 - 12/2016
3	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 05/2022 - 01/2013
3	Inborn Genetic Diseases (Disease, Hereditary) 03/2022 - 01/2003
3	Aortic Aneurysm (Aneurysm, Aortic) 12/2021 - 04/2015
3	Aneurysm (Aneurysms) 01/2021 - 05/2005
3	Rheumatoid Arthritis 01/2021 - 01/2014
2	Vascular Remodeling 12/2021 - 11/2011
2	Ectopia Lentis 01/2021 - 05/2015
2	Hyperlipoproteinemia Type III (Broad Beta Disease) 01/2021 - 01/2013
2	Disease Progression 01/2019 - 04/2005
2	Sudden Death 08/2015 - 12/2009
2	Xanthomatosis (Xanthoma) 08/2014 - 12/2013
2	Hypoxia (Hypoxemia) 11/2011 - 08/2011
2	Fibrosis (Cirrhosis) 08/2011 - 12/2007
2	Diffuse Scleroderma (Progressive Systemic Sclerosis) 08/2011 - 04/2010
2	Connective Tissue Diseases (Connective Tissue Disease) 01/2011 - 11/2010
2	Insulin Resistance 08/2007 - 04/2007
2	Dyspnea (Shortness of Breath) 01/2005 - 10/2004
1	Acromicric dysplasia 11/2022
1	Iron Overload 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Abdominal Aortic Aneurysm 12/2021
1	Hypobetalipoproteinemias (Hypobetalipoproteinemia) 08/2021
1	Lipoprotein Glomerulopathy 01/2021
1	Adenocarcinoma of Lung 01/2021
1	Scoliosis 01/2021
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2021
1	Unstable Angina 01/2020
1	Ischemic Stroke 01/2020
1	Acute Coronary Syndrome 01/2020
1	Neurodevelopmental Disorders 01/2020
1	Myocardial Infarction 01/2020

Drug/Important Bio-Agent (IBA)

14	LDL CholesterolIBA 05/2022 - 06/2003
12	Fibrillin-1IBA 11/2022 - 04/2002
11	Apolipoproteins B (ApoB)IBA 03/2022 - 01/2003
11	ApolipoproteinsIBA 08/2021 - 01/2003
10	Transforming Growth Factor-beta Type II ReceptorIBA 12/2016 - 08/2004
9	Proprotein Convertase 9IBA 01/2020 - 06/2003
9	LDL Receptors (LDL Receptor)IBA 01/2018 - 08/2002
8	oxidized low density lipoproteinIBA 05/2022 - 11/2005
7	CholesterolIBA 10/2017 - 11/2005
6	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 01/2017 - 07/2009
6	Transforming Growth Factor-beta Type I ReceptorIBA 12/2016 - 08/2006
5	Apolipoproteins E (ApoE)IBA 05/2022 - 01/2013
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2007
5	SubtilisinIBA 01/2017 - 11/2010
5	LDL Lipoproteins (beta Lipoproteins)IBA 01/2013 - 04/2009
4	LipidsIBA 10/2017 - 04/2007
3	Triglycerides (Triacylglycerol)IBA 05/2022 - 01/2013
3	Lipoproteins (Lipoprotein)IBA 01/2021 - 01/2019
3	1,3,4,6- tetra- O- acetyl- 2- azido- 2- deoxyglucopyranose (TAAD)IBA 01/2021 - 08/2006
3	AutoantibodiesIBA 01/2014 - 12/2007
3	Biomarkers (Surrogate Marker)IBA 03/2012 - 03/2008
3	FibrillinsIBA 02/2009 - 09/2003
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2022 - 08/2015
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2019
2	Amino Acids FDA Link 04/2020 - 01/2015
2	alirocumabIBA 01/2020 - 12/2015
2	Metalloproteases (Metalloproteinases)IBA 12/2018 - 03/2010
2	AntibodiesIBA 10/2017 - 03/2011
2	Monoclonal AntibodiesIBA 01/2017 - 12/2015
2	Oxidoreductases (Dehydrogenase)IBA 03/2016 - 10/2005
2	Losartan (Cozaar)FDA LinkGeneric 08/2015 - 05/2010
2	Angiotensin Receptor AntagonistsIBA 05/2015 - 05/2010
2	Apolipoprotein B-100 (Apo B 100)IBA 12/2012 - 05/2012
2	erucylphosphocholineIBA 03/2012 - 11/2011
2	CollagenIBA 01/2011 - 11/2010
2	LigandsIBA 07/2009 - 04/2009
2	Transforming Growth Factor beta (TGF-beta)IBA 02/2009 - 12/2007
2	Glucose (Dextrose)FDA LinkGeneric 08/2007 - 04/2007
2	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 08/2006 - 08/2004
2	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2005 - 10/2004
1	IronIBA 01/2022
1	ADAMTS ProteinsIBA 12/2021
1	Protein Kinases (Protein Kinase)IBA 01/2021
1	Methotrexate (Mexate)FDA LinkGeneric 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	Nonsense Codon (Nonsense Mutation)IBA 01/2021
1	Apolipoprotein E2IBA 01/2021
1	ChromatinIBA 01/2020
1	Transforming Growth Factor beta3 (TGF beta 3)IBA 01/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020
1	Fragile X Mental Retardation ProteinIBA 01/2020

Therapy/Procedure

11	Therapeutics 01/2021 - 03/2008
1	Bariatric Surgery 01/2022
1	Lung Transplantation 01/2022
1	Precision Medicine 01/2020